Page last updated: 2024-08-23

pirfenidone and Disease Models, Animal

pirfenidone has been researched along with Disease Models, Animal in 94 studies

Research

Studies (94)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (3.19)	18.2507
2000's	21 (22.34)	29.6817
2010's	48 (51.06)	24.3611
2020's	22 (23.40)	2.80

Authors

Authors	Studies
Braisted, J; Dranchak, P; Earnest, TW; Gu, X; Hoon, MA; Inglese, J; Oliphant, E; Solinski, HJ	1
Chen, L; Li, Y; Liu, K; Ma, T; Ma, X; Sun, H; Sun, X; Wang, C; Zheng, X; Zhu, Y	1
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV	1
C Jacob, HK; Dawra, RK; Dudeja, V; Edwards, DB; Ferrantella, A; George, J; Giri, B; Gomez Aguilar, B; Iyer, S; Jain, T; Maynard, CL; Palathingal Bava, E; Sahay, P; Saluja, AK; Sethi, V; Sharma, P; Tarique, M; Vaish, U	1
Chen, F; Huo, J; Li, S; Meng, Y; Tang, Q; Tian, L; Wang, W; Yang, Q	1
Dawra, RK; Dudeja, V; George, J; Giri, B; Iyer, S; Jain, T; Palathingal Bava, E; Sahay, P; Saluja, AK; Sharma, P; Tarique, M; Vaish, U	1
Ahir, M; Bonnen, MD; Ebrahimpour, A; Eissa, NT; Ghebre, YT; Jegga, AG; Montesi, SB; Raghu, G; Wang, M	1
Aktoz, T; Cevik, G; Dursun, M; Kadioglu, A; Tastekin, E; Tozsin, A	1
Abdel-Aziz, AH; Abdelghany, TM; Ashour, AA; Salah, MM; Salama, SA	1
Chen, J; Huang, Y; Lu, C; Mei, L; Pan, X; Peng, T; Quan, G; Wang, B; Wang, H; Wu, C	1
Bao, Y; Chen, Y; Gao, C; Huang, L; Huang, X; Song, Y; Wu, L; Zhu, S	1
Beers, MF; Duerr, J; Dvornikov, D; Engelmann, TA; Fraumann, SG; Hegermann, J; Herth, FJF; Kawabe, H; Klingmüller, U; Knudsen, L; Konietzke, P; Kreuter, M; Kreutz, C; Leitz, DHW; Mall, MA; Muley, T; Mulugeta, S; Ochs, M; Rotin, D; Seyhan Agircan, A; Szczygiel, M; Wielpütz, MO; Zadora, PK	1
Chang, C; Du, Y; Fang, X; Gao, Y; Li, H; Li, T; Mu, M; Qin, X; Qu, G; Wang, X; Wang, Y; Xu, G; Yu, S; Zhang, Z; Zhu, P	1
Dai, Y; Huang, X; Lv, Q; Ruan, Z; Wang, J; Xu, C	1
Chen, J; Guo, H; Huang, J; Peng, X; Wang, J	1
Seifirad, S	1
Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M	1
Beloki, L; Carruthers, A; Chahboub, A; Clarke, D; Dunmore, R; Güler-Gane, G; Koch, S; Kuziora, M; Lewis, A; Liarte Marin, E; May, R; Miranda, E; Murray, L; Overed-Sayer, C; Parfrey, H; Rassl, D	1
Chen, D; Liu, Y; Sun, Y; Zhang, J; Zhang, X; Zhang, Z; Zhu, D	1
Armendáriz-Borunda, J; Escutia-Gutiérrez, R; García-Bañuelos, J; Monraz-Méndez, CA; Rodríguez-Sanabria, JS; Sandoval-Rodríguez, A; Santos-García, A	1
Ding, Z; Dong, J; Lin, F; Xu, J; Xue, Z; Zhang, B	1
Allard, B; Batteux, F; Blanco, P; Chizzolini, C; Constans, J; Contin-Bordes, C; Duffau, P; Forcade, E; Groppi, A; Henrot, P; Izotte, J; Jeljeli, M; Jolivel, V; Laurent, P; Lazaro, E; Leleu, D; Levionnois, E; Manicki, P; Pradeu, T; Richez, C; Schaeverbeke, T; Seneschal, J; Truchetet, ME	1
Cao, ZJ; Dai, HP; Han, ZF; Li, BC; Li, ZG; Liu, Y; Pang, JL; Qi, XM; Song, MY; Wang, C; Wang, J; Yang, PR; Zhang, XR; Zhang, Z	1
Araya, J; Asano, H; Fujita, Y; Hara, H; Hashimoto, M; Ichikawa, A; Ishikawa, T; Ito, S; Kadota, T; Kaneko, Y; Kobayashi, K; Kurita, Y; Kuwano, K; Minagawa, S; Morikawa, T; Nakayama, K; Numata, T; Odaka, M; Saito, N; Sato, N; Tsubouchi, K; Utsumi, H; Wakui, H; Yamashita, M; Yanagisawa, H; Yoshida, M; Yoshii, Y	1
Harada, Y; Kuga, K; Miyamoto, M; Miyamoto, Y; Sakai, Y; Sato, K; Shimizu, F; Takamatsu, Y; Yasuno, H	1
Mandegary, A; Pardakhty, A; Rajaian, H; Rasooli, R	1
Kamali, Y; Mandegary, A; Nabipour, F; Pourgholamhosein, F; Rasooli, R	1
Hu, H; Li, F; Liu, F; Ma, W; Pan, Q; Ran, C; Wang, J; Yang, Q	1
Adamo, L; Bajpai, G; Barger, PM; Bhattacharya, D; Jiang, W; Kovacs, A; Mann, DL; Matkovich, SJ; Rocha-Resende, C; Schilling, JD; Staloch, LJ; Weinheimer, CJ	1
Carrington, R; Jordan, S; Page, CP; Pitchford, SC	1
Li, L; Liu, B; Qin, W; Tang, Y; Wu, B; Yi, M; Yuan, X	1
Araya, J; Asano, H; Fujita, Y; Hara, H; Hashimoto, M; Hosaka, Y; Ichikawa, A; Ishikawa, T; Ito, S; Kadota, T; Kaneko, Y; Kobayashi, K; Kuwano, K; Minagawa, S; Morikawa, T; Nakayama, K; Nishimura, SL; Numata, T; Odaka, M; Saito, N; Sato, N; Tsubouchi, K; Utsumi, H; Wakui, H; Yamashita, M; Yanagisawa, H; Yoshida, M	1
Chen-Yoshikawa, TF; Date, H; Masuda, S; Okabe, R; Saito, M; Suetsugu, K; Takahagi, A	1
Chen, Q; Huang, W; Ma, Z; Shen, Z; Yu, C; Zhang, H; Zhang, Z; Zhao, C	1
Bordenave, J; Cumont, A; Dorfmüller, P; Ghigna, MR; Guignabert, C; Huertas, A; Humbert, M; Phan, C; Poble, PB; Quatremare, T; Savale, L; Thuillet, R; Tu, L	1
Baynes, R; Khattab, A; Mowat, F; Oh, A; Salmon, B; Westermeyer, HD; Yeatts, J	1
Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Xu, L; Zhuge, F	1
Akduman, B; Bolat, MS; Bulut, E; Cinar, O; Demirkiran, ED; Erdem, S; Girgin, R; Kaymaz, E; Mungan, NA	1
Lin, H; Wu, C; Zhang, X	1
Cha, H; Cho, JM; Kim, HJ; Kim, HR; Kim, YS	1
El-Agamy, DS; El-Kashef, DH; Shaaban, AA	1
Mitori, H; Mizukami, K; Noto, T; Takakura, K; Tomura, Y	1
Collard, HR; Spagnolo, P; Wells, AU	1
Fan, Z; Han, H; Wang, F; Yang, L; Zhang, G	1
Duan, LJ; Gu, X; Huang, T; Kong, XJ; Qi, J; Qian, XQ; Xu, D	1
Haneya, A; Heigel, E; Hirt, SW; Lehle, K; Pfaehler, S; Schmid, C; von Suesskind-Schwendi, M	1
Bollmann, G; Cosín-Roger, J; Fagagnini, S; Hausmann, M; Hünerwadel, A; Lang, S; Lutz, C; Mamie, C; Meier, R; Rogler, G; Tchouboukov, A; Weber, A; Weber, FE	1
Antonia, SJ; Boateng, K; Mediavilla-Varela, M; Noyes, D	1
Chan, HK; Leung, SS; Onoue, S; Seto, Y; Suzuki, G	1
Akcılar, A; Akcılar, R; Bayhan, Z; Kargı, E; Kocak, C; Kocak, FE; Tiryaki, C; Yaylak, F; Zeren, S	1
Jung, KI; Park, CK	1
Bacon, KB; Boehme, SA; DiTirro, DN; Franz-Bacon, K; Ly, TW	1
Gu, C; Li, Z; Liu, X; Nie, Y; Wang, B; Wang, Q; Wen, J	1
Chen, G; Deng, Y; Gu, G; Guo, K; Hu, Q; Li, G; Li, J; Li, R; Li, Y; Ren, J; Wang, G; Wu, L	1
Abel, PW; Casale, TB; Jiang, H; Mehrotra, S; Panettieri, RA; Rennard, S; Toews, ML; Tu, Y; Wolff, DW; Xie, Y; Zhang, Q	1
Calik, E; Guvenal, T; Hasdemir, PS; Koltan, SO; Koyuncu, FM; Ozbilgin, K; Ozkut, M; Uner, MA	1
El-Agamy, DS	1
Guo, F; Song, X; Yu, W	1
Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A	1
Furuke, S; Hata, KI; Ikeda, K; Itoh, M; Komiya, C; Miyachi, Y; Mori, K; Nakabayashi, K; Ochi, K; Ogawa, Y; Shiba, K; Shimazu, N; Suganami, T; Tanaka, M; Tsuchiya, K; Yamaguchi, S	1
Basak, SK; Guha, R; Hazra, S; Khanum, BNMK; Konar, A; Nandi, S; Sur, VP	1
Aquilina, K; Hobbs, C; Thoresen, M; Tucker, A; Whitelaw, A	1
Cho, ME; Kopp, JB	1
Maher, TM	1
Lin, X; Sun, G; Wu, K; Yu, M; Zhong, H	1
Hu, GX; Li, JW; Lu, ZQ; Shen, XW; Sun, W; Tong, SH; Xiao, M; Yu, XC	1
Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD	1
Cagnon, L; Duboux, G; Fioraso-Cartier, L; Gaggini, F; Gradia, A; Heitz, F; Houngninou-Molango, S; Laleu, B; Merlot, C; Orchard, M; Page, P; Szyndralewiez, C	1
Azuma, A; Miyazaki, Y; Mizushima, T; Sato, K; Tanaka, KI	1
Choi, JS; Jung, KI; Kim, HK; Shin, SY	1
Abbasi, H; Aran, S; Ghaffari, A; Keshavarz, A; Seifirad, S; Taslimi, S	1
Al-Bayati, MA; Giri, SN; Margolin, SB; Mohr, FC; Xie, Y	1
Dosanjh, A; Ikonen, T; Morris, RE; Wan, B	1
Brien, JF; Card, JW; Margolin, SB; Massey, TE; Racz, WJ	1
Case, N; Chapman, RW; Crawley, Y; Egan, RW; Fine, J; Hey, JA; Kreutner, W; Kung, T; Minnicozzi, M; Spond, J; Wang, P	1
Bao, L; Cho, IH; Hyun, BH; Kim, YJ; Lee, CH; Margolin, SB; Park, HS; Park, YH	1
Fernandez, F; Jendrisak, M; Margolin, SB; Marshbank, S; McKane, BW; Mohanakumar, T; Narayanan, K	1
Abe, K; Fujii, T; Hayashi, T; Ishii, H; Kadota, J; Kakugawa, T; Kohno, S; Miyazaki, M; Mukae, H; Oku, H	1
McGowan, TA; Sharma, K; Zhu, Y	1
Forslund, T; Iversen, BM; Leh, S; Margolin, SB; Vaagnes, Ø	1
Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H	1
Dosanjh, A	1
Hoey, AJ; Irwin, NG; Van Erp, C	1
Ammar, YA; Bayomi, AH; El-Sehrawi, HM; Ismail, MM; Noaman, E; Shawer, TZ	1
Ding, C; Everett, TH; Guerra, JM; Lee, KW; Olgin, JE; Rahmutula, D; Wilson, E	1
Bratt, JM; Decile, KC; Giri, SN; Grewal, H; Mansoor, JK; Margolin, SB; Pinkerton, KE; Schelegle, ES; Walby, WF	1
Farkas, GA; Gosselin, LE; Personius, K; Williams, JE	1
Chen, XY; Wang, F; Wen, T; Wu, H	1
al-Took, S; Murray, C; Tulandi, T	1
Fukagawa, M; Hata, S; Kuroda, T; Kurokawa, K; Margolin, SB; Shimizu, T	1
Sanderson, SD; Shiels, IA; Taylor, SM	1
Millar, AB; Poole, AR; Thickett, DR	1
Bicknell, GR; Margolin, SB; Murphy, GJ; Nicholson, ML; Sandford, R; Waller, JR	1
Hale, ML; Krakauer, T; Margolin, SB; Roy, CJ; Stiles, BG	1

Reviews

7 review(s) available for pirfenidone and Disease Models, Animal

Article	Year
Use of animal models in IPF research. Pulmonary pharmacology & therapeutics, 2018, Volume: 51 Topics: Animals; Bleomycin; Disease Models, Animal; Drug Development; Drug Evaluation, Preclinical; Idiopathic Pulmonary Fibrosis; Indoles; Pyridones; Respiratory Function Tests	2018
Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug discovery today, 2015, Volume: 20, Issue:5 Topics: Animals; Comorbidity; Disease Models, Animal; Disease Progression; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Risk Factors; Time Factors; Treatment Outcome	2015
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert opinion on investigational drugs, 2010, Volume: 19, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Evaluation; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones	2010
Pirfenidone in idiopathic pulmonary fibrosis. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Disease Models, Animal; Evidence-Based Medicine; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Research Design; Treatment Outcome	2010
Antifibrotic activities of pirfenidone in animal models. European respiratory review : an official journal of the European Respiratory Society, 2011, Volume: 20, Issue:120 Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta	2011
Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Current diabetes reports, 2004, Volume: 4, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Nephropathies; Disease Models, Animal; Humans; Kidney Failure, Chronic; Pyridones; Transforming Growth Factor beta	2004
The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2001, Volume: 18, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Biomarkers; Collagen; Disease Models, Animal; Humans; Inflammation; Interferon-gamma; Lung Diseases, Interstitial; Pulmonary Fibrosis; Pyridones	2001

Trials

1 trial(s) available for pirfenidone and Disease Models, Animal

Article	Year
Safety and efficacy of topically applied 0.5% and 1% pirfenidone in a canine model of subconjunctival fibrosis. Veterinary ophthalmology, 2019, Volume: 22, Issue:4 Topics: Administration, Topical; Animals; Aqueous Humor; Conjunctival Diseases; Disease Models, Animal; Dogs; Drug Implants; Female; Fibrosis; Pyridones; Random Allocation	2019

Other Studies

86 other study(ies) available for pirfenidone and Disease Models, Animal

Article	Year
Inhibition of natriuretic peptide receptor 1 reduces itch in mice. Science translational medicine, 2019, 07-10, Volume: 11, Issue:500 Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, Spinal; Humans; Mice, Inbred C57BL; Mice, Knockout; Neurons; Pruritus; Receptors, Atrial Natriuretic Factor; Reproducibility of Results; Signal Transduction; Small Molecule Libraries	2019
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorganic & medicinal chemistry, 2020, 01-15, Volume: 28, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Idiopathic Pulmonary Fibrosis; Janus Kinase 3; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship	2020
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection	2020
Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. JCI insight, 2022, 01-25, Volume: 7, Issue:2 Topics: Acinar Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Cytokines; Disease Models, Animal; Fibrosis; Interleukin-10; Macrophages; Mice; Pancreas; Pancreatitis; Paracrine Communication; Pyridones; Signal Transduction	2022
The antifibrotic effect of pheretima protein is mediated by the TGF-β1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis. Journal of ethnopharmacology, 2022, Mar-25, Volume: 286 Topics: Animals; Anti-Inflammatory Agents; Bleomycin; Disease Models, Animal; Freeze Drying; Idiopathic Pulmonary Fibrosis; Inflammation; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Oligochaeta; Proteins; Pyridones; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1	2022
Pirfenidone ameliorates chronic pancreatitis in mouse models through immune and cytokine modulation. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2022, Volume: 22, Issue:5 Topics: Acute Disease; Animals; Arginine; Ceruletide; Collagen; Cytokines; Disease Models, Animal; Fibrosis; Humans; Mice; Pancreatitis, Chronic; Pyridones	2022
Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis. Scientific reports, 2022, 11-30, Volume: 12, Issue:1 Topics: Animals; Disease Models, Animal; Esomeprazole; Idiopathic Pulmonary Fibrosis; Mice; Prospective Studies; Proton Pump Inhibitors; Retrospective Studies; Transforming Growth Factor beta	2022
The Effect of Pirfenidone on Peyronie Plaques and Erectile Function in a Peyronie's Rat Model. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2023, Volume: 33, Issue:11 Topics: Animals; Disease Models, Animal; Erectile Dysfunction; Humans; Male; Penile Induration; Penis; Rats; Rats, Sprague-Dawley	2023
Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice. Life sciences, 2019, Dec-15, Volume: 239 Topics: Animals; Collagen Type II; Collagen Type IV; Concanavalin A; Disease Models, Animal; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Pyridones; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha	2019
A pirfenidone loaded spray dressing based on lyotropic liquid crystals for deep partial thickness burn treatment: healing promotion and scar prophylaxis. Journal of materials chemistry. B, 2020, 04-01, Volume: 8, Issue:13 Topics: Animals; Antifibrinolytic Agents; Bandages; Burns; Cells, Cultured; Cicatrix; Disease Models, Animal; Humans; Liquid Crystals; Male; Mice; Mice, Inbred BALB C; Particle Size; Pyridones; Surface Properties; Wound Healing	2020
Pirfenidone ameliorates the formation of choroidal neovascularization in mice. Molecular medicine reports, 2020, Volume: 21, Issue:5 Topics: Animals; Choroid; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fluorescent Antibody Technique; Intravitreal Injections; Lasers; Male; Mice; Mice, Inbred C57BL; Pyridones; Retina; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A	2020
Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. Nature communications, 2020, 04-24, Volume: 11, Issue:1 Topics: Adult; Aged; Animals; Biopsy; Disease Models, Animal; Epithelial Cells; Epithelial Sodium Channels; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mice; Mice, Knockout; Middle Aged; Mucin-5B; Nedd4 Ubiquitin Protein Ligases; Proteomics; Pyridones; Ubiquitination	2020
Pirfenidone alleviates lipopolysaccharide-induced lung injury by accentuating BAP31 regulation of ER stress and mitochondrial injury. Journal of autoimmunity, 2020, Volume: 112 Topics: Acute Lung Injury; Alveolar Epithelial Cells; Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Lipopolysaccharides; Male; Membrane Proteins; Mice; Mitochondria; Primary Cell Culture; Pulmonary Alveoli; Pyridones; Respiratory Distress Syndrome	2020
Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways. Molecular medicine (Cambridge, Mass.), 2020, 05-24, Volume: 26, Issue:1 Topics: Animals; Cell Survival; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Humans; Lung; Male; Mice; Pulmonary Fibrosis; Pyridones; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1; Wnt Signaling Pathway	2020
The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms. The Prostate, 2020, Volume: 80, Issue:12 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Polarity; Chronic Disease; Chronic Pain; Cytokines; Disease Models, Animal; Inflammation Mediators; Lipid Peroxidation; Macrophages; Male; NF-kappa B; Pelvic Pain; Phosphorylation; Prostatitis; Pyridones; Rats; Syndrome	2020
Pirfenidone: A novel hypothetical treatment for COVID-19. Medical hypotheses, 2020, Volume: 144 Topics: Alveolar Epithelial Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; Apoptosis; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Disease Models, Animal; Down-Regulation; Drug Repositioning; Humans; Lipid Peroxidation; Oxidative Stress; Pyridones; Receptors, Virus	2020
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:5 Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation	2021
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects. Thorax, 2020, Volume: 75, Issue:9 Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cell Proliferation; Cell Survival; Chemokine CCL2; Coculture Techniques; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Mast Cells; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Rats; Recombinant Proteins; Signal Transduction; Stem Cell Factor; Vital Capacity	2020
Pirfenidone inhibits fibroblast proliferation, migration or adhesion and reduces epidural fibrosis in rats via the PI3K/AKT signaling pathway. Biochemical and biophysical research communications, 2021, 04-02, Volume: 547 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Epidural Space; Fibrosis; Humans; Laminectomy; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridones; Rats; Rats, Sprague-Dawley; Signal Transduction	2021
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH. Scientific reports, 2021, 06-03, Volume: 11, Issue:1 Topics: Animals; Biomarkers; Collagen Type I; Cytokines; Disease Models, Animal; Disease Susceptibility; Fatty Liver; Gene Expression Regulation; Immunohistochemistry; Inflammation Mediators; Lipid Metabolism; Liver Function Tests; Male; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Pyridones	2021
Macrophage-mediated degradable gelatin-coated mesoporous silica nanoparticles carrying pirfenidone for the treatment of rat spinal cord injury. Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 37 Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Gelatin; Humans; Macrophages; Nanoparticles; Pyridones; Rats; Rats, Sprague-Dawley; Recovery of Function; Silicon Dioxide; Spinal Cord; Spinal Cord Injuries	2021
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis. Annals of the rheumatic diseases, 2021, Volume: 80, Issue:12 Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression Profiling; Humans; Interleukin-10; Lectins, C-Type; Lymphocytes; Male; Mice; Middle Aged; Myofibroblasts; Pyridones; Receptors, Immunologic; Scleroderma, Systemic; Skin; Transforming Growth Factor beta	2021
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:4 Topics: Animals; Disease Models, Animal; Fibrosis; Inflammation; Interleukin-17; Janus Kinases; Lung; Mice; Mice, Inbred C57BL; Pneumonia; Pyridones; Signal Transduction; Silicon Dioxide; STAT Transcription Factors	2022
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory research, 2017, 06-02, Volume: 18, Issue:1 Topics: Animals; Antioxidants; Autophagy; Autophagy-Related Proteins; Bleomycin; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Humans; Lung; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Mitophagy; Myofibroblasts; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Pyridones; Reactive Oxygen Species; Receptors, Platelet-Derived Growth Factor; RNA Interference; Signal Transduction; Transfection; Ubiquitin-Protein Ligases	2017
The abdominal skin of female Sprague-Dawley rats is more sensitive than the back skin to drug-induced phototoxicity. Journal of pharmacological and toxicological methods, 2017, Volume: 88, Issue:Pt 1 Topics: Abdomen; Administration, Oral; Animals; Back; Dermatitis, Phototoxic; Disease Models, Animal; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Histones; Methoxsalen; Phosphoproteins; Pyridones; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Skin; Sunlight; Tandem Mass Spectrometry; Toxicity Tests, Acute	2017
Preference of Aerosolized Pirfenidone to Oral Intake: An Experimental Model of Pulmonary Fibrosis by Paraquat. Journal of aerosol medicine and pulmonary drug delivery, 2018, Volume: 31, Issue:1 Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Male; Oxidative Stress; Paraquat; Pulmonary Fibrosis; Pyridones; Rats; Rats, Sprague-Dawley	2018
Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis. Inflammation, 2018, Volume: 41, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Cytoprotection; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Glucocorticoids; Hydroxyproline; Inflammation Mediators; Lung; Male; Matrix Metalloproteinase 2; Oxidative Stress; Paraquat; Prednisolone; Pulmonary Fibrosis; Pyridones; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2018
A Novel Rabbit Model for Benign Biliary Stricture Formation and the Effects of Medication Infusions on Stricture Formation. Digestive diseases and sciences, 2018, Volume: 63, Issue:10 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antineoplastic Agents; Biliary Tract Diseases; Constriction, Pathologic; Disease Models, Animal; Drug Evaluation, Preclinical; Pyridones; Rabbits; Secondary Prevention; Sirolimus; Vasodilator Agents	2018
Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. JCI insight, 2018, 06-07, Volume: 3, Issue:11 Topics: Animals; B-Lymphocyte Subsets; Diphtheria Toxin; Disease Models, Animal; Female; Heart Ventricles; Humans; Lipopolysaccharides; Lymphocyte Activation; Lymphocyte Depletion; Mice; Myocardial Infarction; Myocardium; Pyridones; Reperfusion Injury; Ventricular Remodeling	2018
Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. Radiation research, 2018, Volume: 190, Issue:4 Topics: Animals; Body Weight; Collagen; Disease Models, Animal; Female; Kaplan-Meier Estimate; Longevity; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Radiation, Ionizing; Radiotherapy; Signal Transduction; Transforming Growth Factor beta1	2018
PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy, 2019, Volume: 15, Issue:3 Topics: Animals; Cell Cycle Proteins; Cell Line; Cellular Senescence; Cigarette Smoking; Disease Models, Animal; Epithelial Cells; Humans; Lung; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Mitochondria; Mitophagy; Nuclear Proteins; Protein Kinases; PTEN Phosphohydrolase; Pulmonary Disease, Chronic Obstructive; Pyridones; Reactive Oxygen Species; Ubiquitin-Protein Ligases	2019
Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model. The Journal of thoracic and cardiovascular surgery, 2019, Volume: 158, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Cytokines; Cytoprotection; Disease Models, Animal; Inflammation Mediators; Lung; Lung Injury; Lung Transplantation; Male; Pyridones; Rats, Wistar; Reperfusion Injury; Signal Transduction; Warm Ischemia	2019
Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulmonary pharmacology & therapeutics, 2018, Volume: 53 Topics: Animals; Bleomycin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; p38 Mitogen-Activated Protein Kinases; Pyridones; Rats; Rats, Sprague-Dawley; Smad3 Protein; Transforming Growth Factor beta1	2018
Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:3 Topics: Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Extracellular Matrix; Humans; Hypertension, Pulmonary; Hypoxia; Lung; Male; Muscle, Smooth, Vascular; Pulmonary Artery; Pyridones; Rats; Rats, Wistar; Vascular Remodeling	2019
Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. Laboratory investigation; a journal of technical methods and pathology, 2019, Volume: 99, Issue:9 Topics: Animals; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Pyridones; RAW 264.7 Cells	2019
The effect of an antifibrotic agent, pirfenidone, on penile erectile function in an experimental rat model of ischemic priapism. International journal of impotence research, 2020, Volume: 32, Issue:2 Topics: Administration, Oral; Animals; Disease Models, Animal; Electric Stimulation; Fibrosis; Ischemia; Male; Photomicrography; Priapism; Pyridones; Random Allocation; Rats; Rats, Wistar	2020
Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3). International immunopharmacology, 2019, Volume: 74 Topics: Activating Transcription Factor 3; Adult; Aged; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Cell Differentiation; Cell Movement; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Fibroblasts; Gene Knockdown Techniques; Humans; Lung; Lung Diseases, Interstitial; Male; Mice, Inbred C57BL; Middle Aged; Myofibroblasts; Pulmonary Fibrosis; Pyridones	2019
The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models. Molecules (Basel, Switzerland), 2019, Jul-31, Volume: 24, Issue:15 Topics: Animals; Biguanides; Bleomycin; Disease Models, Animal; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Mice; Pyridones; Republic of Korea	2019
Protective role of pirfenidone against experimentally-induced pancreatitis. Pharmacological reports : PR, 2019, Volume: 71, Issue:5 Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Apoptosis; Arginine; Cytokines; Disease Models, Animal; Male; Mice; Oxidative Stress; Pancreas; Pancreatic Function Tests; Pancreatitis; Pyridones	2019
Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis. European journal of pharmacology, 2014, Aug-15, Volume: 737 Topics: Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Gene Expression Regulation; Glomerular Basement Membrane; Glomerulonephritis; Male; Proteinuria; Pyridones; Rats; RNA, Messenger	2014
Functionalized graphene oxide as a drug carrier for loading pirfenidone in treatment of subarachnoid hemorrhage. Colloids and surfaces. B, Biointerfaces, 2015, May-01, Volume: 129 Topics: Animals; Blood-Brain Barrier; Brain; Cell Survival; Disease Models, Animal; Drug Carriers; Graphite; Mice; Oxides; PC12 Cells; Pyridones; Rats; Subarachnoid Hemorrhage; Treatment Outcome	2015
Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction. Molecular medicine reports, 2015, Volume: 12, Issue:3 Topics: Animals; Disease Models, Animal; Fibrosis; Male; Pyridones; Rats, Sprague-Dawley; Urinary Bladder; Urinary Bladder Neck Obstruction	2015
Protective function of pirfenidone and everolimus on the development of chronic allograft rejection after experimental lung transplantation. Histology and histopathology, 2016, Volume: 31, Issue:7 Topics: Allografts; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Everolimus; Graft Rejection; Immunosuppressive Agents; Lung Transplantation; Male; Oxidative Stress; Pyridones; Rats; Rats, Inbred F344; Rats, Inbred WKY	2016
Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis. Inflammatory bowel diseases, 2016, Volume: 22, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cell Proliferation; Collagen; Disease Models, Animal; Female; Fibrosis; Immunoenzyme Techniques; Intestinal Diseases; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Transforming Growth Factor beta	2016
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC cancer, 2016, Mar-02, Volume: 16 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Synergism; Fibroblasts; Humans; Neoplasms; Pyridones; Transforming Growth Factor beta; Xenograft Model Antitumor Assays	2016
Development of an Improved Inhalable Powder Formulation of Pirfenidone by Spray-Drying: In Vitro Characterization and Pharmacokinetic Profiling. Pharmaceutical research, 2016, Volume: 33, Issue:6 Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Chromatography, Liquid; Desiccation; Disease Models, Animal; Drug Compounding; Male; Ovalbumin; Particle Size; Peroxidase; Pneumonia; Powders; Pyridones; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Technology, Pharmaceutical	2016
Antiadhesive and anti-inflammatory effects of pirfenidone in postoperative intra-abdominal adhesion in an experimental rat model. The Journal of surgical research, 2016, Volume: 201, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Male; Matrix Metalloproteinase 9; Peritoneum; Postoperative Complications; Pyridones; Random Allocation; Rats, Sprague-Dawley; Tissue Adhesions; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2016
Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation. Drug design, development and therapy, 2016, Volume: 10 Topics: Animals; Cicatrix; Disease Models, Animal; Fibrosis; Foreign-Body Reaction; Glaucoma Drainage Implants; Pyridones; Rabbits; Wound Healing	2016
MAP3K19 Is a Novel Regulator of TGF-β Signaling That Impacts Bleomycin-Induced Lung Injury and Pulmonary Fibrosis. PloS one, 2016, Volume: 11, Issue:5 Topics: A549 Cells; Animals; Bleomycin; Bronchoalveolar Lavage; Cell Line, Tumor; Disease Models, Animal; Epithelial Cells; Female; HeLa Cells; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Lung Injury; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2016
Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis. Nephrology (Carlton, Vic.), 2017, Volume: 22, Issue:8 Topics: Actins; Animals; Antigens, CD; Cadherins; Cell Line; Collagen Type I; Collagen Type III; Disease Models, Animal; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Fibronectins; Fibrosis; Humans; JNK Mitogen-Activated Protein Kinases; Kidney Diseases; Kidney Tubules, Proximal; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridones; Rats, Sprague-Dawley; Renal Agents; S100 Calcium-Binding Protein A4; Transforming Growth Factor beta1; Ureteral Obstruction	2017
Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model. Biochemical pharmacology, 2016, Oct-01, Volume: 117 Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Proliferation; Cell Survival; Colitis; Collagen; Colon; Disease Models, Animal; Female; Fibrosis; Gastrointestinal Agents; Humans; Intestinal Mucosa; Mice, Inbred C57BL; Pyridones; Random Allocation; Signal Transduction; Specific Pathogen-Free Organisms; Transforming Growth Factor beta	2016
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respiratory research, 2016, 08-22, Volume: 17, Issue:1 Topics: Animals; Bleomycin; Calcium Signaling; Cell Line; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Profiling; Humans; Idiopathic Pulmonary Fibrosis; Lung; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Pyridones; RGS Proteins; RNA, Messenger; Thrombin; Time Factors; Transfection; Up-Regulation	2016
Effect of Pirfenidone on Vascular Proliferation, Inflammation and Fibrosis in an Abdominal Adhesion Rat Model. Journal of investigative surgery : the official journal of the Academy of Surgical Research, 2017, Volume: 30, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Female; Inflammation; Injections, Intraperitoneal; Interleukin-17; Neovascularization, Pathologic; Peritoneum; Postoperative Complications; Pyridones; Rats; Rats, Wistar; Tissue Adhesions; Transforming Growth Factor beta; Treatment Outcome; Uterus	2017
Pirfenidone ameliorates concanavalin A-induced hepatitis in mice via modulation of reactive oxygen species/nuclear factor kappa B signalling pathways. The Journal of pharmacy and pharmacology, 2016, Volume: 68, Issue:12 Topics: Animals; Antioxidants; Biomarkers; Chemical and Drug Induced Liver Injury; Concanavalin A; Cytoprotection; Disease Models, Animal; Hepatitis, Autoimmune; Liver; Male; Mice; NF-kappa B; Oxidative Stress; Pyridones; Reactive Oxygen Species; Signal Transduction	2016
Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models. Pharmaceutical biology, 2017, Volume: 55, Issue:1 Topics: Acetylcysteine; Animals; Bleomycin; Blotting, Western; Caveolin 1; Cytoprotection; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Idiopathic Pulmonary Fibrosis; Lung; Male; Platelet-Derived Growth Factor; Prednisone; Protective Agents; Pyridones; Rats, Wistar; Real-Time Polymerase Chain Reaction; Signal Transduction; Time Factors; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2017
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood, 2017, 05-04, Volume: 129, Issue:18 Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta	2017
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Scientific reports, 2017, 03-17, Volume: 7 Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cells, Cultured; Diet, Western; Disease Models, Animal; Feeding Behavior; Hepatocytes; Humans; Inflammation; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pyridones; Receptor, Melanocortin, Type 4; Tumor Necrosis Factor-alpha; Up-Regulation	2017
Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Eye (London, England), 2017, Volume: 31, Issue:9 Topics: Actins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Collagen Type I; Cytokines; Disease Models, Animal; Electroretinography; Eye Injuries, Penetrating; Fluorescent Antibody Technique, Indirect; Gene Expression Regulation; Intravitreal Injections; Pyridones; Rabbits; Real-Time Polymerase Chain Reaction; Retina; Vitreoretinopathy, Proliferative; Vitreous Body	2017
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model? Acta paediatrica (Oslo, Norway : 1992), 2008, Volume: 97, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Dilatation, Pathologic; Disease Models, Animal; Losartan; Pyridones; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta	2008
Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. Investigative ophthalmology & visual science, 2011, May-16, Volume: 52, Issue:6 Topics: Actins; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Movement; Cell Proliferation; Cicatrix; Collagen; Conjunctival Diseases; Disease Models, Animal; Drug Evaluation; Endothelium, Corneal; Glaucoma; Intraocular Pressure; Mitomycin; Ophthalmic Solutions; Postoperative Complications; Proliferating Cell Nuclear Antigen; Pyridones; Rabbits; Trabeculectomy; Tumor Necrosis Factor-alpha	2011
[The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice]. Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases, 2011, Volume: 29, Issue:2 Topics: Animals; Disease Models, Animal; Lung; Male; Mice; Mice, Inbred ICR; Paraquat; Pulmonary Fibrosis; Pyridones; Transforming Growth Factor beta	2011
Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorganic & medicinal chemistry, 2011, Dec-01, Volume: 19, Issue:23 Topics: Administration, Oral; Animals; Azepines; Bleomycin; Disease Models, Animal; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred C57BL; NADPH Oxidase 1; NADPH Oxidase 4; NADPH Oxidases; Oxazines; Pulmonary Fibrosis; Pyrazines; Pyridones; Structure-Activity Relationship	2011
Effects of lecithinized superoxide dismutase and/or pirfenidone against bleomycin-induced pulmonary fibrosis. Chest, 2012, Volume: 142, Issue:4 Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Free Radical Scavengers; Lung; Mice; Phosphatidylcholines; Pulmonary Fibrosis; Pyridones; Superoxide Dismutase; Treatment Outcome; Vital Capacity	2012
Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits. Current eye research, 2012, Volume: 37, Issue:9 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Follow-Up Studies; Inflammation; Oculomotor Muscles; Postoperative Complications; Pyridones; Rabbits; Strabismus; Transforming Growth Factor beta; Wound Healing	2012
Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats. Clinical toxicology (Philadelphia, Pa.), 2012, Volume: 50, Issue:8 Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Ascorbic Acid; Disease Models, Animal; Herbicides; Injections, Intraperitoneal; Injections, Intravenous; Life Expectancy; Male; Paraquat; Pulmonary Fibrosis; Pyridones; Rats; Rats, Wistar; Survival Rate; Vitamin E	2012
Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochemical pharmacology, 2002, Aug-01, Volume: 64, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Drug Interactions; Fibrosis; Kidney Diseases; Male; Pyridones; Rats; Rats, Sprague-Dawley; Vanadates	2002
Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulmonary pharmacology & therapeutics, 2002, Volume: 15, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclosporine; Cytokines; Cytotoxicity Tests, Immunologic; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Graft Rejection; Immunosuppressive Agents; Pyridones; Rats; Rats, Inbred Lew; Staining and Labeling; Trachea	2002
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicological sciences : an official journal of the Society of Toxicology, 2003, Volume: 75, Issue:1 Topics: Acute Disease; Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Bleomycin; Cricetinae; Disease Models, Animal; Hydroxyproline; Male; Membrane Potentials; Mitochondria; Oxygen Consumption; Pulmonary Fibrosis; Pyridones; RNA, Messenger; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1	2003
Inhibition of experimental acute pulmonary inflammation by pirfenidone. Pulmonary pharmacology & therapeutics, 2003, Volume: 16, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Guinea Pigs; Humans; Interleukin-6; Lipopolysaccharides; Male; Mice; Pneumonia; Pulmonary Disease, Chronic Obstructive; Pyridones; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha	2003
Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. Journal of Korean medical science, 2003, Volume: 18, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis; Kidney; Kidney Diseases; Male; Mice; Proteinuria; Pyridones; Sclerosis; Time Factors	2003
Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Transplantation, 2004, Mar-15, Volume: 77, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Chronic Disease; Disease Models, Animal; Graft Rejection; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Postoperative Complications; Pyridones; Trachea; Transplantation, Homologous	2004
Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. The European respiratory journal, 2004, Volume: 24, Issue:1 Topics: Analysis of Variance; Animals; Biopsy, Needle; Bleomycin; Disease Models, Animal; HSP70 Heat-Shock Proteins; Hydroxyproline; Immunohistochemistry; Injections, Intravenous; Male; Mice; Mice, Inbred Strains; Probability; Pulmonary Fibrosis; Pyridones; Random Allocation; Reference Values; Sensitivity and Specificity	2004
Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:1 Topics: Analysis of Variance; Animals; Antibodies; Autoantibodies; Base Sequence; Benzimidazoles; Biopsy, Needle; Biphenyl Compounds; Blood Chemical Analysis; Blood Pressure Determination; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Glomerulonephritis; Immunohistochemistry; Kidney Function Tests; Male; Molecular Sequence Data; Probability; Pyridones; Random Allocation; Rats; Rats, Wistar; Reference Values; Renal Circulation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Statistics, Nonparametric; Tetrazoles	2005
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:10 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta	2005
Pirfenidone and chronic progressive obliterative airway disease. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2006, Volume: 25, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Cyclosporine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Immunosuppressive Agents; Mice; Proteins; Pyridones; Rats	2006
Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle & nerve, 2006, Volume: 34, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Disease Models, Animal; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Myocardium; Pyridones; RNA, Messenger; Transforming Growth Factor beta; Ventricular Dysfunction, Left	2006
Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis. Archiv der Pharmazie, 2006, Volume: 339, Issue:8 Topics: Administration, Oral; Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Aminotransferases; Bleomycin; Bronchoalveolar Lavage Fluid; Creatinine; Dihydropyridines; Disease Models, Animal; Hydroxyproline; Intubation, Intratracheal; L-Lactate Dehydrogenase; Lung; Male; Molecular Structure; Pulmonary Fibrosis; Pyridones; Rats; Time Factors; Urea	2006
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation, 2006, Oct-17, Volume: 114, Issue:16 Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Heart Failure; Pyridones	2006
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma. Pulmonary pharmacology & therapeutics, 2007, Volume: 20, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchi; Bronchial Hyperreactivity; Bronchial Provocation Tests; Collagen; Disease Models, Animal; Inflammation; Lung; Male; Mucins; Muscle, Smooth; Ovalbumin; Pyridones; Random Allocation; Rats; Rats, Inbred BN; Respiratory Mucosa; Transforming Growth Factor beta	2007
A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. Muscle & nerve, 2007, Volume: 35, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Collagen; Disease Models, Animal; Fibrosis; In Vitro Techniques; Isometric Contraction; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Pyridones; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1	2007
Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2008, Volume: 57, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Galactosamine; Inflammation; Lipid Peroxidation; Lipopolysaccharides; Liver; Liver Diseases; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Pyridones; Rats; Rats, Sprague-Dawley; Severity of Illness Index	2008
Effects of pirfenidone and dermoid cyst fluid on adhesion formation. Fertility and sterility, 1998, Volume: 69, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dermoid Cyst; Disease Models, Animal; Female; Injections, Intraperitoneal; Ovarian Neoplasms; Prospective Studies; Pyridones; Rats; Rats, Sprague-Dawley; Tissue Adhesions; Uterine Diseases	1998
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney international, 1998, Volume: 54, Issue:1 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Collagen; Disease Models, Animal; Fibrosis; Gelatinases; Hydroxyproline; Inulin; Kidney Cortex; Kidney Function Tests; Ligation; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Pyridones; Rats; Rats, Sprague-Dawley; RNA, Messenger; RNA, Ribosomal, 18S; RNA, Ribosomal, 28S; Transforming Growth Factor beta; Ureter; Ureteral Obstruction	1998
Arterially perfused eye model of uveitis. Australian veterinary journal, 1999, Volume: 77, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cats; Ciliary Arteries; Clonixin; Complement C5a; Disease Models, Animal; Dogs; Eye; Female; Histamine; Horse Diseases; Horses; Hydrogen Peroxide; Indomethacin; Intraocular Pressure; Ketoprofen; Male; Perfusion; Pyridones; Uveitis	1999
Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2002, Volume: 23, Issue:3 Topics: Angioplasty, Balloon; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carotid Arteries; Carotid Artery Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Matrix; Gene Expression; Male; Metalloendopeptidases; Pyridones; Rats; Time Factors; Tunica Intima	2002
Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infection and immunity, 2002, Volume: 70, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cells, Cultured; Disease Models, Animal; Enterotoxins; Humans; Interferon-gamma; Interleukin-1; Interleukin-6; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred BALB C; Pyridones; Shock, Septic; Staphylococcal Infections; Staphylococcus aureus; Superantigens; T-Lymphocytes; Tumor Necrosis Factor-alpha	2002